Novo Nordisk has announced plans to eliminate approximately 9,000 employees globally, 11 percent of its 78,400-person workforce, in a restructuring designed to generate $1.25 billion in annual savings by late 2026. The cuts are particularly concentrated in Denmark, where 5,000 positions are being reduced, and in US operations including manufacturing, quality, HR, regulatory, legal, medical affairs, and compliance functions. The company's new CEO is leading a strategic refocus: reinvesting the savings from these cuts into commercial execution, R&D, and manufacturing scale-up to meet the extraordinary global demand for GLP-1 obesity and diabetes medications.
The context matters here. Novo Nordisk is not a struggling company. Ozempic and Wegovy have made it one of the most valuable pharmaceutical companies in the world. The cuts are not a sign of financial distress, they are a reallocation. The company is removing organizational layers and support functions to concentrate investment in the areas directly driving its most valuable products forward. The people in HR, compliance, legal, and medical affairs are paying the price for a strategic pivot, not for any failure on their part.
The professionals leaving Novo Nordisk are emerging from one of the most carefully watched pharmaceutical companies in the world at a moment when the obesity and metabolic disease space is being transformed by exactly the drugs Novo made. That domain knowledge, regulatory, clinical, commercial, is in extraordinary demand from the dozens of companies now trying to compete in this space.
The GLP-1 market has triggered a gold rush in the pharmaceutical industry. Dozens of companies are racing to develop competing obesity, diabetes, and metabolic disease treatments, and they desperately need people with deep experience in this therapeutic area and in the regulatory and commercial infrastructure required to bring those products to market. Former Novo Nordisk professionals are among the most sought-after advisors in this space right now.
Medical affairs and regulatory affairs directors from Novo Nordisk are advising biotech companies on FDA and EMA submission strategy, clinical trial design, and label negotiations at $225 to $425 per hour. Commercial operations leaders with GLP-1 launch and market access experience are being retained by pharma companies entering the obesity space at $15,000 to $30,000 per month. Manufacturing quality professionals with experience at Novo's production scale are consulting with pharmaceutical manufacturers expanding capacity to meet demand.
The specificity of your Novo Nordisk experience in diabetes and obesity therapeutics is a premium asset right now. This is not a generic pharma consulting market, it is a specific moment in a specific therapeutic area where your knowledge is genuinely rare and the demand is intense.
Novo Nordisk directors and senior managers in pharmaceutical operations typically earned $170,000 to $320,000 in total compensation, with meaningful variation based on function and geography. US-based commercial and medical affairs leaders often reached $280,000 to $450,000. The Danish operations compensation structure reflects European norms, which tend toward stronger severance protections and longer notice periods.
To establish your consulting rate: if your gross revenue goal is $280,000 (which nets approximately $200,000 after taxes and benefits), and you plan to bill 1,000 hours in your first year, you need to charge $280 per hour. For GLP-1 and metabolic disease specialists, the market will support $300 to $400 per hour from the outset, the demand is that specific and the supply of qualified practitioners is that limited.
Plan your transition with an understanding that pharmaceutical regulatory and medical affairs work often involves multi-month project cycles. An advisory engagement for a company preparing an FDA submission might run four to six months at a meaningful monthly retainer. Thinking in terms of projects rather than hourly billing will serve you better in this market.
You worked inside the company that changed how the world thinks about obesity and metabolic disease. The drugs you supported, the regulatory pathways you navigated, and the commercial strategies you built are now being studied and replicated by every major pharmaceutical company in the world. That context is not background noise, it is the center of your positioning.
For medical affairs and regulatory professionals, the most powerful positioning right now is direct: "I help pharmaceutical companies developing GLP-1 and metabolic disease therapies navigate the regulatory and medical affairs infrastructure required to bring those drugs to market." There is a defined, large, and urgent market of buyers who need exactly that.
For commercial, HR, compliance, and legal professionals, the positioning is slightly broader: "I help pharmaceutical companies that are scaling rapidly in a new therapeutic area build the internal infrastructure, compliance, HR, legal, operations, that keeps them from falling apart as they grow." The context of Novo Nordisk's growth provides the proof that you have operated inside exactly that kind of environment.
We read your experience, identify your positioning, and extract the results that matter to clients. Your resume becomes the seed of everything.
In minutes you see what your experience is worth, what you should be charging, and what is standing between you and your first client.
Your positioning, website, content, and tools are ready. Answer questions over time and everything gets sharper the more you use it.
Start free. See what your experience is worth. Upgrade when you're ready to start making money independently.
Upload your resume. In two minutes you will see what your experience is worth as a consultant and exactly how to go get it.